CHICAGO, IL — For decades, a pancreatic cancer diagnosis was treated as a death sentence. The disease is notoriously silent, spreading before most patients even realize something is wrong. But on May 31, 2026, a standing ovation rang out inside a convention hall in Chicago — and it may have signaled the beginning of the end of that grim reality.
Researchers presented results from the Phase 3 RASolute 302 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting, showing that a once-daily oral pill called daraxonrasib nearly doubled survival in patients with advanced pancreatic cancer — from 6.7 months on standard chemotherapy to 13.2 months.
